EP Wealth Advisors LLC Boosts Position in Gilead Sciences, Inc. (NASDAQ:GILD)

EP Wealth Advisors LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,459 shares of the biopharmaceutical company’s stock after acquiring an additional 527 shares during the quarter. EP Wealth Advisors LLC’s holdings in Gilead Sciences were worth $3,256,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. CarsonAllaria Wealth Management Ltd. boosted its stake in shares of Gilead Sciences by 198.3% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 238 shares in the last quarter. Palisade Asset Management LLC purchased a new stake in Gilead Sciences in the first quarter worth about $29,000. Cedar Wealth Management LLC lifted its holdings in Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 160 shares during the period. Financial Connections Group Inc. bought a new stake in Gilead Sciences during the 2nd quarter valued at approximately $34,000. Finally, Frank Rimerman Advisors LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth approximately $36,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD opened at $83.84 on Tuesday. The firm has a market cap of $104.45 billion, a PE ratio of 232.89, a P/E/G ratio of 2.91 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The firm has a fifty day simple moving average of $78.28 and a two-hundred day simple moving average of $71.60.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.61 by $0.40. The firm had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were paid a $0.77 dividend. The ex-dividend date of this dividend was Friday, September 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.67%. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on GILD. Robert W. Baird restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Thursday, June 20th. Royal Bank of Canada boosted their target price on shares of Gilead Sciences from $72.00 to $74.00 and gave the company a “sector perform” rating in a report on Wednesday, September 4th. BMO Capital Markets increased their price target on shares of Gilead Sciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Piper Sandler reissued an “overweight” rating and set a $95.00 price target on shares of Gilead Sciences in a research report on Wednesday, September 11th. Finally, Truist Financial upped their price objective on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Twelve analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $82.06.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.